No. of patients treated so far, page-7

All theoretical but it would be interesting to look at comparative long-term outcomes.

I'd hypothesise that OLP-1002 could be a good option in the short-medium term, but if people get some pain relief and then keep destroying that joint, eventually they'll be in a worse place than where they started.

I really hope that PAR are also collecting SAS data on how many people are avoiding joint replacements compared to a control population not receiving the drug. If there was a distinct difference the governing bodies wouldn't be able to ignore it, though I suspect the Orthopods may not be too happy.